OTTAWA, Jan. 19 /CNW/ - The following is a statement by Russell Williams, President of Canada's Research-Based Pharmaceutical Companies (Rx&D), on the release of a report entitled "Innovation for a Better Tomorrow: Closing Canada's Intellectual Property
Gap" by the Canadian Intellectual Property Council (CIPC) and the Canadian
Chamber of Commerce.
"This report "Innovation for a Better Tomorrow: Closing Canada's Intellectual Property
Gap" puts forward concrete and achievable steps to bridge the innovation gap
and create opportunities in the knowledge economy. We commend both the
Canadian Intellectual Property Council (CIPC) and the Canadian Chamber
of Commerce for their comprehensive investigation of this exceedingly
complex issue and their recommendations to improve the intellectual
property regime in this country."
"Globally each year, about $100 billion is invested in life sciences
research. By taking action to improve intellectual property rights,
Canada will send a clear signal to the world that we are serious about
beating the competition and capturing a greater share of this
investment and the jobs that go with it.
"Intellectual property rights (IPR) are the cornerstone of innovation.
Developing and bringing a new treatment to market can often take ten to
twelve years and cost about $1 billion. A predictable and
internationally competitive intellectual property regime will create
major incentives for innovative pharmaceutical companies to conduct
more research and perform more clinical trials here in Canada in
collaboration with governments, research institutions and universities.
"The work of the Chamber and the CIPC also builds upon the increasing
body of evidence provided by the Coalition for Action on Innovation in
Canada and others that improving IPR will give Canada a competitive
advantage in the global marketplace.
"Strengthening intellectual property safeguards also has the potential
to improve the health of Canadians by making new medicines and vaccines
available to patients to treat cancer, Alzheimer's, diabetes and other
chronic disease. As well, new medicines reduce workplace disability and
save on health care costs for surgery, hospitalization and doctor
"The report contains three recommendations that would improve the
research environment in Canada immediately. These include: providing
innovative companies an effective right to appeal an adverse court
decision to provide a level playing field, improving data protection
regulations and providing patent term restoration to offset regulatory
delays. The duration of patent protection would remain the same if
these changes were implemented. We look forward to working with CIPC,
the Chamber and governments to begin implementing these
Rx&D is the association of leading research-based pharmaceutical
companies dedicated to improving the health of Canadians through the
discovery and development of new medicines and vaccines. Our community
represents 15,000 men and women working for 50 member companies and
invests more than $1 billion in research and development each year to
fuel Canada's knowledge-based economy. Guided by our Code of Ethical
Practices, our membership is committed to working in partnership with
governments, healthcare professionals and stakeholders in a highly
SOURCE Canada's Research-Based Pharmaceutical Companies
For further information: